Thermo Fisher Scientific CD20 Monoclonal Antibody (QCH6A7), Brilliant Ultra Violet 661, eBioscience

Applications

Tested Dilution

Publications

Flow Cytometry (Flow)

1.0 µg/test

-

Product Specifications

Species Reactivity

Mouse

Host/Isotype

Rat / IgG2a, kappa

Class

Monoclonal

Type

Antibody

Clone

QCH6A7

Conjugate

Brilliant Ultra Violet™ 661 Brilliant Ultra Violet™ 661 Brilliant Ultra Violet™ 661

View additional formats

• APC
• Brilliant Violet 421
• PE
• PerCP-eFluor 710
• Request custom conjugation

Excitation/Emission Max

349/659 nm View spectra

Form

Liquid

Concentration

0.2 mg/mL

Purification

Affinity chromatography

Storage buffer

PBS, pH 7.2, with BSA

Contains

0.09% sodium azide

Storage conditions

4° C, store in dark, DO NOT FREEZE!

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_2942139

Product Specific Information

Description: The monoclonal antibody QCH6A7 reacts with mouse CD20. CD20 is a B cell specific, 32-kDa membrane protein that is expressed on late pro-B cells through memory B cells in the B cell lineage. CD20 is not found on hematopoietic stem cells, early pro-B cells or later mature plasma cells. CD20 is involved in intracellular calcium regulation and plays a role in B cell proliferation. CD20 is intially expressed after the induction of CD19 during development and is coexpressed with IgM during the pre-B to immature B cell transition in bone marrow. Expression of CD20 increases during maturation with almost all mature B cells expressing some level of CD20. Unlike other B cell antigens, CD20 is not shed or internalized upon antibody binding. Monoclonal antibodies against the CD20 antigen may be used to deplete B cells and CD20 has proven to be an effective immunotheraputic target in B cell lymphomas and several autoimmune diseases including rheumatoid arthritis and type I diabetes. CD20 consists of 4 transmembrane domains and a 44 amino acid extracellular domain which contains the QCH6A7 epitope.

Staining with clone QCH6A7 provides significantly improved staining intensity compared to clone AISB12 in flow cytometric assays.

Applications Reported: This QCH6A7 antibody has been reported for use in flow cytometric analysis.

Applications Tested: This QCH6A7 antibody has been tested by flow cytometric analysis of mouse splenocytes and mouse bone marrow cells. This may be used at less than or equal to 1.0 µg per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.

Brilliant Ultra Violet™ 661 (BUV661) is a tandem dye that emits at 660 nm and is intended for use on cytometers equipped with an ultraviolet (355 nm) laser. Please make sure that your instrument is capable of detecting this fluorochrome.

When using two or more Super Bright, Brilliant Violet™, Brilliant Ultra Violet™, or other polymer dye-conjugated antibodies in a staining panel, it is recommended to use Super Bright Complete Staining Buffer (Product # SB-4401-42) or Brilliant Stain Buffer™ (Product # 00-4409-75) to minimize any non-specific polymer interactions. Please refer to the datasheet for Super Bright Staining Buffer or Brilliant Stain Buffer for more information.

Light sensitivity: This tandem dye is sensitive to photo-induced oxidation. Please protect this vial and stained samples from light.

Fixation: Samples can be stored in IC Fixation Buffer (Product # 00-8222-49) (100 µL of cell sample + 100 µL of IC Fixation Buffer) or 1-step Fix/Lyse Solution (00-5333-54) for up to 3 days in the dark at 4°C with minimal impact on brightness and FRET efficiency/compensation. Some generalizations regarding fluorophore performance after fixation can be made, but clone-specific performance should be determined empirically.

Excitation: 350 nm; Emission: 660 nm; Laser: Ultraviolet Laser.

BRILLIANT ULTRA VIOLET™ is a trademark or registered trademark of Becton, Dickinson and Company or its affiliates, and is used under license. Powered by Sirigen™.

Target Information

CD20 is a non-glycosylated surface phosphoprotein that has a molecular weight range of 33-37 kDa depending on the degree of phosphorylation. CD20 is expressed on mature and most malignant B cells, in a subpopulation of T lymphocytes and follicular dendritic cells. CD20 expression on B cells is synchronous with the expression of surface IgM and it regulates transmembrane calcium conductance, cell cycle progression and B-cell proliferation. CD20 is also associated with lipid rafts, but the intensity of this association depends on extracellular triggering, employing CD20 conformational change, and/or BCR (B cell antigen receptor) aggregation. After the receptor ligation, BCR and CD20 colocalize and then rapidly dissociate before BCR endocytosis, whereas CD20 remains at the cell surface. CD20 serves as a useful target for antibody-mediated therapeutic depletion of B cells, as it is expressed at high levels on most B-cell malignancies, but does not become internalized or shed from the plasma membrane following monoclonal antibody treatment. Diseases associated with CD20 dysfunction include Ms4a1-related common variable immune deficiency.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.